Peregrine Capital Management LLC Makes New $3.99 Million Investment in ADMA Biologics, Inc. (NASDAQ:ADMA)

Peregrine Capital Management LLC acquired a new stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 882,983 shares of the biotechnology company's stock, valued at approximately $3,991,000. Peregrine Capital Management LLC owned approximately 0.39% of ADMA Biologics as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. State Street Corp grew its stake in shares of ADMA Biologics by 217.9% in the third quarter. State Street Corp now owns 9,423,422 shares of the biotechnology company's stock worth $22,899,000 after acquiring an additional 6,459,197 shares during the period. Millennium Management LLC grew its stake in shares of ADMA Biologics by 206.7% in the fourth quarter. Millennium Management LLC now owns 5,296,781 shares of the biotechnology company's stock worth $20,552,000 after acquiring an additional 3,569,778 shares during the period. Point72 Asset Management L.P. bought a new stake in shares of ADMA Biologics in the fourth quarter worth approximately $7,725,000. Stonepine Capital Management LLC grew its stake in shares of ADMA Biologics by 38.8% in the fourth quarter. Stonepine Capital Management LLC now owns 6,940,000 shares of the biotechnology company's stock worth $26,927,000 after acquiring an additional 1,940,000 shares during the period. Finally, Norges Bank bought a new stake in shares of ADMA Biologics in the fourth quarter worth approximately $6,958,000. 75.68% of the stock is currently owned by institutional investors.

Insider Transactions at ADMA Biologics

In other news, Director Steve Elms sold 407,000 shares of the business's stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $6.21, for a total value of $2,527,470.00. Following the transaction, the director now owns 3,208,671 shares of the company's stock, valued at $19,925,846.91. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Over the last quarter, insiders have sold 639,895 shares of company stock valued at $3,927,169. 6.00% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

ADMA has been the topic of a number of research reports. HC Wainwright reissued a "buy" rating and issued a $7.50 price objective (up previously from $6.00) on shares of ADMA Biologics in a report on Tuesday, March 26th. Cantor Fitzgerald raised their price objective on shares of ADMA Biologics from $6.50 to $8.00 and gave the stock an "overweight" rating in a report on Thursday, February 29th. Finally, Mizuho raised their price objective on shares of ADMA Biologics from $9.00 to $10.00 and gave the stock a "buy" rating in a report on Friday, March 1st. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, ADMA Biologics presently has a consensus rating of "Buy" and an average price target of $7.88.

ADMA Biologics Price Performance

NASDAQ:ADMA traded down $0.20 during trading hours on Friday, hitting $6.02. 1,475,275 shares of the stock traded hands, compared to its average volume of 2,682,325. The company has a quick ratio of 1.69, a current ratio of 5.16 and a debt-to-equity ratio of 1.04. ADMA Biologics, Inc. has a 1 year low of $3.06 and a 1 year high of $6.76. The company has a market cap of $1.37 billion, a price-to-earnings ratio of -46.23 and a beta of 0.46. The stock has a 50 day moving average price of $5.85 and a 200 day moving average price of $4.66.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported $0.04 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.02. ADMA Biologics had a negative net margin of 10.94% and a positive return on equity of 0.49%. The business had revenue of $73.90 million for the quarter, compared to the consensus estimate of $73.50 million. Sell-side analysts forecast that ADMA Biologics, Inc. will post 0.3 EPS for the current fiscal year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.